placebo + Omega-3 carboxylic acids + Dapagliflozin + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
T2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin)
Conditions
T2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin)
Trial Timeline
Jan 1, 2015 → Dec 1, 2015
NCT ID
NCT02279407About placebo + Omega-3 carboxylic acids + Dapagliflozin + Placebo
placebo + Omega-3 carboxylic acids + Dapagliflozin + Placebo is a phase 2 stage product being developed by AstraZeneca for T2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin). The current trial status is completed. This product is registered under clinical trial identifier NCT02279407. Target conditions include T2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin).
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02279407 | Phase 2 | Completed |
Competing Products
20 competing products in T2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin)